Janet Dancey

National Cancer Institute

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “ctDNA response after pembrolizumab in non-small cell lung cancer: phase 2 adaptive trial results”.

ctDNA response after pembrolizumab in non-small cell lung cancer: phase 2 adaptive trial results

Nature Medicine(2023)10.1038/s41591-023-02598-9

N/A

3.7DataRank · unranked

151 citations

Cheryl Ho, Garth Nicholas, Rosalyn A. Juergens, Adrian G. Sacher, Andrea S. Fung +15 more

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

European Journal of Cancer(2009)10.1016/j.ejca.2008.10.026

N/A

1.5DataRank · unranked

29148 citations

P. Therasse, J. Bogaerts, L.H. Schwartz, D. Sargent, R. Ford +25 more

Phase I/II study of sorafenib in combination with erlotinib for recurrent glioblastoma as part of a 3-arm sequential accrual clinical trial: NABTC 05-02

Neuro-Oncology Advances(2020)10.1093/noajnl/vdaa124

N/A

0DataRank · unranked

22 citations

John G. Kuhn, Kathleen R. Lamborn, Lauren E. Abrey, Lisa M. DeAngelis, Frank S. Lieberman +14 more